Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Active Psoriatic Arthritis (SELECT - PsA 2)
NCT03104374Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of upadacitinib in psoriatic arthritis (PsA), sponsored by AbbVie Inc.. Started May 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03104374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104374.